Fabry Disease Screening in ESRD Patient… | Clinical Trial

Key information

Conditions

ESRD Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Cardiovascular Diseases Central Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders Chronic Disease Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disease Attributes Fabry Disease Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Genetic Diseases, X-Linked Kidney Diseases Kidney Failure, Chronic Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipidoses Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Male Urogenital Diseases Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Sphingolipidoses Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year–70 year

Sex eligibility

Male

Study type

Observational

Primary location

CHU de Rennes

Rennes, 35033, France

About this study

Detection of Fabry disease is done by dried blood spot test, in dialyzed and transplanted men, who reached ESRD for vascular or unknown disease and were not previously screened.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men less than 70 years old
ESRD treated by dialysis or kidney graft in one of the 4 following regions : Bretagne, Centre, Pays de la Loire and Poitou-Charentes
For unknown nephropathy OR vascular nephropathy and/or diabetic nephropathy unproved by biopsy
Agreeing freely to participate in the study

Exclusion criteria

Men less than 18 years old
Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

Treatment and study plan

Dried blood spot test

Other

Primary outcomes

To detect Fabry disease by dried blood spot test, in dialyzed and transplanted men, who reached ESRD for vascular or unknown disease and were not previously screened

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Official study title

Fabry Disease Prevalence in End-stage Renal Disease (ESRD) Patients on Dialysis or Transplant in West of France

Acronym: SNOUFY

Important dates

Study start: 2016
Primary completion: 2018
Study completion: 2018
First posted: Mar 25, 2016
Registry last updated: Aug 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed